MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9500
-0.0700
-6.86%
After Hours: 0.9500 0 0.00% 16:54 05/24 EDT
OPEN
1.020
PREV CLOSE
1.020
HIGH
1.020
LOW
0.9300
VOLUME
356.74K
TURNOVER
0
52 WEEK HIGH
11.18
52 WEEK LOW
0.9000
MARKET CAP
50.60M
P/E (TTM)
-0.4515
1D
5D
1M
3M
1Y
5Y
GOEV, SUNW and APPH among pre market gainers
Rattler Midstream RTLR +14% Diamondback Energy to buy Rattler Midstream in all-stock deal. Spirit Airlines SAVE +14% on new tender offer from JetBlue. AgriFORCE Growing Systems (AGRI) +15%. NanoViricides (NNVC) +14% reports that it has
Seekingalpha · 05/16 12:26
Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions
Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission...
American City Business Journals · 05/10 11:37
Better Therapeutics, Great Elm top healthcare gainers; TherapeuticsMD, Sutro Biopharma lead losers' pack
Gainers: Better Therapeutics (BTTX) +34%. Great Elm (GEG) +9%. Nuvectis Pharma (NVCT) +8%. Viatris (VTRS) +5%. BioNTech (BNTX) +3%. Losers: TherapeuticsMD (TXMD) -30%. Sutro Biopharma (STRO) -12%. NanoViricides (NNVC) -12%. RedHill Biopharma (RDHL) -10%. F...
Seekingalpha · 05/09 14:02
BRIEF-RedHill Biopharma Announces $15 Million Registered Direct Offering With A Leading Healthcare Investor
reuters.com · 05/09 12:57
RedHill Biopharma to raise $15M in equity offering
RedHill Biopharma (NASDAQ:RDHL) announced Monday a direct stock offering to raise up to $15M in gross proceeds. That is to come through the issue of 10.56M American Depositary Shares (ADS), priced at
Seekingalpha · 05/09 12:43
RedHill Biopharma Announces $15M Registered Direct Offering With A Leading Healthcare Investor
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading
Benzinga · 05/09 12:35
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of ...
PR Newswire · 05/09 12:30
Cathie Wood’s Latest Portfolio: 10 New Stock Picks in 2022
In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment con...
Insider Monkey · 05/06 15:20
More
No Data
Learn about the latest financial forecast of RDHL. Analyze the recent business situations of Redhill Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RDHL stock price target is 14.38 with a high estimate of 22.00 and a low estimate of 7.00.
High22.00
Average14.38
Low7.00
Current 0.9500
EPS
Actual
Estimate
-0.48-0.36-0.24-0.12
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 64
Institutional Holdings: 8.76M
% Owned: 16.45%
Shares Outstanding: 53.26M
TypeInstitutionsShares
Increased
12
161.25K
New
2
888.66K
Decreased
16
361.48K
Sold Out
10
819.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Finance Director
Einav Nagar-Brenner
Chief Operating Officer
Gilead Raday
Senior Vice President/Director of Sales/Director of Marketing
Rob Jackson
Senior Vice President
Patricia Anderson
Senior Vice President
Reza Fathi
Senior Vice President
Robert Gilkin
Senior Vice President
David Wasserman
Chief Scientific Officer
June Almenoff
Vice President - Finance
Todd Krzyzaniak
Vice President/Director of Human Resources
Michelle Snelling
Vice President
Danielle Abramson
Vice President
Aida Bibliowicz
Vice President
Ben Martie
Vice President
Shani Maurice
Vice President
Craig Miller
Vice President
Steven Thomasian
Vice President
Reginald Williams
Other/Director
Rick Scruggs
Other
Adi Frish
Other
Guy Goldberg
Independent Director
Shmuel Cabilly
Independent Director
Alessandro Della Cha
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
No Data
No Data
About RDHL
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.